EFSA concluded vitamin K2, in the oil formulation it tested, is bioavailable as a source of vitamin K and that the menaquinone-rich edible oil was safe for use in foods and supplements except baby foods and infant formula.
The opinion was the “go-ahead signal” its clients had been waiting for to “step up commercial activities”, said NattoPharma president and CEO, Egil Greve.
Frost & Sullivan handed NattoPharma’s K2 version, MenaQ7, its Product Innovation of the Year Award for an ingredient that delivered clinically backed heart and bone health benefits. It was a “nice recognition”, a NattoPharma spokesperson said.
